LOS ANGELES, CA / ACCESSWIRE / September 29, 2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against IntelliPharmaCeutics International Inc. ("IntelliPharmaCeutics" or the "Company") (IPCI) for possible violations of federal securities laws from January 14, 2016 through July 26, 2017, inclusive (the "Class Period"). Investors, who purchased or otherwise acquired IntelliPharmaCeutics shares during the Class Period, should contact the firm by September 29, 2017, the lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at email@example.com.
No class has been certified in the above action yet, and until a class is certified, you are not considered to be represented by an attorney. You may also choose to do nothing and be an absent class member.
The Complaint alleges that, throughout the Class Period, IntelliPharmaCeutics made false and/or misleading statements and/or failed to disclose: that the Company failed to conduct a human abuse liability study to support its Rexista New Drug Application ("NDA"); that IntelliPharmaCeutics did not include abuse-deterrent studies conducted to suppose abuse-deterrent label claims related to abuse of the drug by various pathways; that the Company was not submitting sufficient data to support approval of the NDA; and that, as a result of the above, the Company's statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis. Following this news, IntelliPharmaCeutics' share price fell materially, which caused investors harm according to the lawsuit.
Lundin Law PC was established by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.
SOURCE: Lundin Law PC